Trends in chronic myeloid leukemia incidence and survival in the United States from 1975 to 2009

Yiming Chen, Haijun Wang, Hagop Kantarjian, Jorge Cortes

Research output: Contribution to journalReview article

Abstract

The use of interferon-α and allogeneic stem cell transplant and more recently of tyrosine kinase inhibitors (TKIs) have improved the outcome of patients with chronic myeloid leukemia (CML). We performed a population-based study of CML to evaluate relative survival (RS) trend by treatment eras. All instances of CML diagnosed between 1975 and 2009 reported in the Surveillance, Epidemiology and End Results databases were reviewed. The incidence of CML was 1.75/100 000 persons per year and increased with age. The incidence was highest in Detroit and lowest among Asians. The 5-year RS ratios increased from 0.26 in patients diagnosed in 19751989 to 0.36 in 19902000 and 0.56 in 20012009. There was a significant improvement in 5-year RS ratios in the 20052009 calendar period compared to the 20012004 period (p < 0.05), corresponding to the introduction of second-generation TKIs. Age was the most important prognostic factor for RS, but the improvement in 5-year RS ratios was observed in all age groups except the group aged < 15 years (p > 0.05), including adolescents and young adults and elderly patient groups. There are ethnic and geographic variations in the incidence of CML. The RS improved with each treatment era, with the greatest improvement in all age groups occurring during the TKI era.

Original languageEnglish (US)
Pages (from-to)1411-1417
Number of pages7
JournalLeukemia and Lymphoma
Volume54
Issue number7
DOIs
StatePublished - Jul 1 2013
Externally publishedYes

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Survival
Incidence
Protein-Tyrosine Kinases
Interferons
Young Adult
Epidemiology
Stem Cells
Age Groups
Databases
Transplants
Therapeutics
Population

Keywords

  • CML
  • Imatinib
  • Incidence
  • Survival
  • TKI
  • Transplant

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Trends in chronic myeloid leukemia incidence and survival in the United States from 1975 to 2009. / Chen, Yiming; Wang, Haijun; Kantarjian, Hagop; Cortes, Jorge.

In: Leukemia and Lymphoma, Vol. 54, No. 7, 01.07.2013, p. 1411-1417.

Research output: Contribution to journalReview article

Chen, Yiming ; Wang, Haijun ; Kantarjian, Hagop ; Cortes, Jorge. / Trends in chronic myeloid leukemia incidence and survival in the United States from 1975 to 2009. In: Leukemia and Lymphoma. 2013 ; Vol. 54, No. 7. pp. 1411-1417.
@article{e0a2fb3d695b4dac84eddb8f55a02db8,
title = "Trends in chronic myeloid leukemia incidence and survival in the United States from 1975 to 2009",
abstract = "The use of interferon-α and allogeneic stem cell transplant and more recently of tyrosine kinase inhibitors (TKIs) have improved the outcome of patients with chronic myeloid leukemia (CML). We performed a population-based study of CML to evaluate relative survival (RS) trend by treatment eras. All instances of CML diagnosed between 1975 and 2009 reported in the Surveillance, Epidemiology and End Results databases were reviewed. The incidence of CML was 1.75/100 000 persons per year and increased with age. The incidence was highest in Detroit and lowest among Asians. The 5-year RS ratios increased from 0.26 in patients diagnosed in 19751989 to 0.36 in 19902000 and 0.56 in 20012009. There was a significant improvement in 5-year RS ratios in the 20052009 calendar period compared to the 20012004 period (p < 0.05), corresponding to the introduction of second-generation TKIs. Age was the most important prognostic factor for RS, but the improvement in 5-year RS ratios was observed in all age groups except the group aged < 15 years (p > 0.05), including adolescents and young adults and elderly patient groups. There are ethnic and geographic variations in the incidence of CML. The RS improved with each treatment era, with the greatest improvement in all age groups occurring during the TKI era.",
keywords = "CML, Imatinib, Incidence, Survival, TKI, Transplant",
author = "Yiming Chen and Haijun Wang and Hagop Kantarjian and Jorge Cortes",
year = "2013",
month = "7",
day = "1",
doi = "10.3109/10428194.2012.745525",
language = "English (US)",
volume = "54",
pages = "1411--1417",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - Trends in chronic myeloid leukemia incidence and survival in the United States from 1975 to 2009

AU - Chen, Yiming

AU - Wang, Haijun

AU - Kantarjian, Hagop

AU - Cortes, Jorge

PY - 2013/7/1

Y1 - 2013/7/1

N2 - The use of interferon-α and allogeneic stem cell transplant and more recently of tyrosine kinase inhibitors (TKIs) have improved the outcome of patients with chronic myeloid leukemia (CML). We performed a population-based study of CML to evaluate relative survival (RS) trend by treatment eras. All instances of CML diagnosed between 1975 and 2009 reported in the Surveillance, Epidemiology and End Results databases were reviewed. The incidence of CML was 1.75/100 000 persons per year and increased with age. The incidence was highest in Detroit and lowest among Asians. The 5-year RS ratios increased from 0.26 in patients diagnosed in 19751989 to 0.36 in 19902000 and 0.56 in 20012009. There was a significant improvement in 5-year RS ratios in the 20052009 calendar period compared to the 20012004 period (p < 0.05), corresponding to the introduction of second-generation TKIs. Age was the most important prognostic factor for RS, but the improvement in 5-year RS ratios was observed in all age groups except the group aged < 15 years (p > 0.05), including adolescents and young adults and elderly patient groups. There are ethnic and geographic variations in the incidence of CML. The RS improved with each treatment era, with the greatest improvement in all age groups occurring during the TKI era.

AB - The use of interferon-α and allogeneic stem cell transplant and more recently of tyrosine kinase inhibitors (TKIs) have improved the outcome of patients with chronic myeloid leukemia (CML). We performed a population-based study of CML to evaluate relative survival (RS) trend by treatment eras. All instances of CML diagnosed between 1975 and 2009 reported in the Surveillance, Epidemiology and End Results databases were reviewed. The incidence of CML was 1.75/100 000 persons per year and increased with age. The incidence was highest in Detroit and lowest among Asians. The 5-year RS ratios increased from 0.26 in patients diagnosed in 19751989 to 0.36 in 19902000 and 0.56 in 20012009. There was a significant improvement in 5-year RS ratios in the 20052009 calendar period compared to the 20012004 period (p < 0.05), corresponding to the introduction of second-generation TKIs. Age was the most important prognostic factor for RS, but the improvement in 5-year RS ratios was observed in all age groups except the group aged < 15 years (p > 0.05), including adolescents and young adults and elderly patient groups. There are ethnic and geographic variations in the incidence of CML. The RS improved with each treatment era, with the greatest improvement in all age groups occurring during the TKI era.

KW - CML

KW - Imatinib

KW - Incidence

KW - Survival

KW - TKI

KW - Transplant

UR - http://www.scopus.com/inward/record.url?scp=84877736487&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877736487&partnerID=8YFLogxK

U2 - 10.3109/10428194.2012.745525

DO - 10.3109/10428194.2012.745525

M3 - Review article

C2 - 23121646

AN - SCOPUS:84877736487

VL - 54

SP - 1411

EP - 1417

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 7

ER -